CliffBio
small molecule

SUBOXONE

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyIndivior →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUBOXONE
Active ingredientBUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
StrengthEQ 8MG BASE;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalOctober 2002
Marketing statusDISCN

More from Indivior

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.